THE BUSINESS OF BIOTECH
Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.
On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs.
ABOUT THE BUSINESS OF BIOTECH
Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success.
MEET YOUR HOST
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute.
Interested in joining us on air? Contact us
RECENT EPISODES
